Schedule a Call

Blog

How Patients View Current + Upcoming Weight Loss Options: A Summary of our Thrivable Q3 365 Report

Thrivable

Thrivable

Research Reports

The incretin market is evolving rapidly, giving patients more treatment options while making decisions more complex. Our latest Thrivable 365 report, titled How Patients View Current + Upcoming Weight Loss Options, combines conjoint, attitudinal, and patient-voice research to examine what motivates patients to begin GLP-1 weight-loss treatment, how they evaluate oral and injectable therapies, and where access, affordability, and product positioning may shape future market opportunities.

To view a preview of this report, please fill out the form below.

What you get

  • Executive Summary: The four headline findings from the study, at a glance.

  • Introduction: Why the incretin matters now, and the trade-offs patients are weighing.

  • About the Study: Who we talked to, and how the research was fielded. 

About the author

Thrivable

Thrivable

Thrivable is the new standard for patient insights — the cardiometabolic patient intelligence partner that helps diabetes and life sciences teams understand patients faster, more representatively, and with more confidence.

people illustration 15
Unlock the Moments That Matter Most to Patients
people illustration 13